La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ProKidney a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ProKidney..

ProKidney (NASDAQ:PROK) Azioni, Catena delle Opzioni

ProKidney

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PROK

RDNT

TCMD

RSI ai minimi e quotazioni in calo: quali aziende del settore medico potrebbero presto rialzarsi e offrire interessanti opportunità?

Occasioni nel settore sanitario: 3 titoli pronti per un rimbalzo

ProKidney Corp. - Class A Ordinary Shares

ProKidney Corp

Press Releases

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

Earnings

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

Health Care

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

ADC Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Inhibrx Biosciences

Jade Biosciences

Kamada

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Organogenesis Holdings

RAPT Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Comments

ProKidney

ProKidney (PROK) Opzioni

ProKidney (NASDAQ:PROK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO